| Identification | Back Directory | [Name]
PM-43I | [CAS]
1637532-77-4 | [Synonyms]
PM-43I
(S)-PM-43I
Propanoic acid, 2,2-dimethyl-, 1,1'-[[[difluoro[4-[(1E)-3-[[(3S)-hexahydro-1-[2-(methylphenylamino)-2-oxoethyl]-2-oxo-1H-azepin-3-yl]amino]-1-methyl-3-oxo-1-propen-1-yl]phenyl]methyl]phosphinylidene]bis(oxymethylene)] ester | [Molecular Formula]
C38H50F2N3O10P | [MOL File]
1637532-77-4.mol | [Molecular Weight]
777.79 |
| Chemical Properties | Back Directory | [Boiling point ]
849.9±65.0 °C(Predicted) | [density ]
1.27±0.1 g/cm3(Predicted) | [form ]
Solid | [pka]
12.88±0.20(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
PM-43I is a potent STAT6 inhibitor and can reduce STAT6 phosphorylation level. PM-43I can be used in allergic lung disease, allergic rhinitis, chronic pulmonary obstructive disease and cancer research[1] sup>. | [in vivo]
PM-43I (intranasal administration; 5 μg per mouse; every other day; 18 d) activity is restricted to the lung by intranasal administration[1]. | Animal Model: | Mice injected with Ovalhumin/Alum[1] | | Dosage: | 5 μg per mouse | | Administration: | Intranasal administration; 5 μg per mouse; every other day; 18 days | | Result: | Showed no effect on the sensisization of peripheral spleenocytes to ovalbumin. |
| [References]
[1] John S. Mcmurray, et al. Stat6 inhibitors. WO2014182928A2. |
|
|